Research article · 15 Apr 2026
Conference abstractPublished 29 Jul 2013
Renal nerve denervation: Nephrologists perspective
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
I nadequately controlled hypertension has significant implications on adverse patient outcomes and healthcare cost. Renal Nerve Denervation (RND) is a non-pharmacological endovascular approach in treating hypertension. Two randomized studies have been published on RND that have shown reduction in systolic and diastolic blood pressure in 6 months. The studies have not analyzed mortality, renal or cardiovascular outcomes. The procedure involves ablation of the sympathetic nerves to the kidney which alters renal blood flow and decreases the afferent sympathetic outflow. The long term effects of these alterations in renal hemodynamics are unclear at this point. Despite the flaws in the study design, all the trials on revascularization of ARVD (Atherosclerotic renal vascular disease) have not shown any benefit over optimal medical therapy. However, a onetime procedure with minimal procedural risk might be an acceptable alternative to 2 or 3 additional life-long antihypertensive medications. Since the procedure has a direct effect on renal hemodynamics, it is extremely important for the Nephrologists to be part of the decision making process to choose the ideal candidate for RND. More information on safety and outcomes would be available after the SIMPLICITY-3 trial is published. If RND is approved in the United States, patient recruitment for the procedure should be performed only in Hypertension Specialty clinics which is staffed by a Nephrologist and a Cardiologist of whom one should be a hypertension specialist certified by the American Society of Hypertension.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Saravanan Bala”

